$NXL News

Nexalin Technology Announces Fourth Peer-Reviewed Publication in Alzheimer's Disease: 15 mA DIFS™ Significantly Improves Sleep Quality in Patients with Mild Alzheimer's Disease

Nexalin Technology Announces Publication Of Fourth Peer-Reviewed Article Reporting Results From Clinical Research On 15 mA DIFS Technology In Alzheimer's Disease

Nexalin Technology Regains Compliance with Nasdaq Minimum Bid Price Requirement; Nasdaq Hearings Panel Grants Request for Continued Listing

Nexalin Technology Signs South America Distribution Agreement for Nexalin Sync Commercialization

Why Is Nexalin Technology Stock Gaining Thursday?

Nexalin Technology Signs Definitive Exclusive Distribution and Local Manufacturing Agreement for Brazil and South America, Marking a Major Step in its Transition Toward Commercial Revenue Generation

Nexalin Signs 10-Year Exclusive Distribution Deal With Inovanexa Medical Technologies Covering Seven Latin American Markets

Nexalin Technology Taps Neuromodulation Commercial Executive Robert DiTota to Advise on its Global Commercialization Strategy

Nexalin Technology Announces New Secondary Analysis of Previously Published Clinical Trial Data Reveals Previously Unreported Improvements in Memory, Comprehension and Language Function in Alzheimer’s Patients; ADAS-Cog Subscale Analysis to Guide Design of Planned U.S. Alzheimer’s Pilot Study

Nexalin Technology Announces Reverse Stock Split

Nexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company’s Proprietary DIFS™ Platform

Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of Life

Nexalin Technology To Present Clinical Data Showing 77.8% Anxiety Response Rate, Durable 8-Week Benefits, And No Serious Adverse Events From Its 15 mA, 77.5 Hz DIFS Deep-Brain Stimulation Platform, At 2026 NYC Neuromodulation Conference

Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sales Plan.

EXCLUSIVE: Nexalin Brazil Trial Shows Benefits Across Anxiety, Sleep And Quality Of Life

Nexalin Technology Completes 8-Week Clinical Study Of Neurostimulation Protocol In Adults With Generalized Anxiety Disorder, Comorbid Insomnia

EXCLUSIVE: Nexalin Brazil Trial Shows Benefits Across Anxiety, Sleep And Quality Of Life

Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia

Nexalin Technology Announces New U.S. Patent Covering Dynamic Frequency Deep-Brain Neurostimulation For Anxiety, Depression, And Insomnia Treatment

Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain Injury